Physician profile
Bennie Jeng
NPI 1104852870
$78,296.84
in general payments reported to CMS, 2019-2025
9 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,425 · 2020: $55K · 2021: $7,078 · 2022: $6,848 · 2023: $650 · 2024: $4,866 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,867 · Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,866.66 |
| Food and Beverage | $111.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $65,024.17 | 2020-2023 | |
| Kedrion Biopharma, INC. | $4,800.00 | 2024 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Sanofi US Services INC. | $4,500.50 | 2021-2022 | |
| Kedrion Biopharma INC. | $2,025.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $850.00 | 2025 | |
| Dompe US, INC. | $677.77 | 2024-2025 | Oxervate |
| W. L. Gore & Associates, INC. | $400.00 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bennie Jeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.